CAPTRUST Financial Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

CAPTRUST Financial Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10	Closed	–	–	5218
2022 Q1	$0	Buy	+10	New	+$157	﹤0.01%	5218
2021 Q4	–	Sell	-13	Closed	–	–	4981
2021 Q3	$0	Sell	13 -152	-92%	-$2.43K	﹤0.01%	4817
2021 Q2	$3K	Sell	165 -931	-85%	-$18.5K	﹤0.01%	4077
2021 Q1	$25K	Buy	1,096 +931	+564%	+$26K	﹤0.01%	2872
2020 Q4	$4K	Hold	165	–	–	﹤0.01%	2957
2020 Q3	$7K	Hold	165	–	–	﹤0.01%	2440
2020 Q2	$8K	Buy	+165	New	+$12.7K	﹤0.01%	2280
2019 Q4	–	Sell	-280	Closed	-$19K	–	1903
2019 Q3	$19K	Buy	+280	New	+$18.8K	﹤0.01%	1327
2018 Q4	–	Sell	-50	Closed	-$6K	–	1697
2018 Q3	$6K	Buy	+50	New	+$5.29K	﹤0.01%	1342

Other funds holding ICPT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

CAPTRUST Financial Advisors's ICPT Position: Q2 2022 in Review

CAPTRUST Financial Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2022, closing a stake of 10 shares.

CAPTRUST Financial Advisors first reported a position in ICPT in Q3 2018 and held it in 9 quarters. The position peaked at $25K in Q1 2021. 144 funds tracked by Wall St. Rank hold ICPT as of Q2 2022.

CAPTRUST Financial Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
CAPTRUST Financial Advisors sold 10 Intercept Pharmaceuticals, Inc. shares in Q2 2022.
CAPTRUST Financial Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2018 and held it in 9 quarters.
CAPTRUST Financial Advisors's Intercept Pharmaceuticals, Inc. position peaked at $25K in Q1 2021.
144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2022, filed 16 Aug 2022.